RBQM Podcast Series | Episode 3: Staying within the Guardrails: How to Push the Boundaries in a Highly Regulated Industry

By designing quality into trials, we focus on the most critical data and create a framework for efficiently identifying and addressing any risks to patients, the integrity of data, or regulatory compliance. While part of regulatory guidance, consistent interpretation of RBQM approaches by regulatory inspectors is an area of concern. In such a highly regulated industry that is notably slow to adopt change, biopharmaceutical companies and CROs are still debating how to go with evidence-backed documentation to satisfy regulatory requirements when using risk-based approaches.

In the third episode of our RBQM podcast series, Amy Kissam-Sands, Senior Vice President of Clinical Operations, John Bell, Chief Quality Officer, and Dr. Kristin Murphy, Senior Director and Global Head of the Change and Adoption Center of Excellence, discuss how to work within the regulatory guardrails when establishing a risk assessment framework.

 

Return to Insights Center

Related Insights

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Regulatory acceptability of AI: Current perspectives

Mar 7, 2024

Blog

Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)

Mar 7, 2024

Blog

Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle

Mar 7, 2024

Blog

Leveraging the draft FDA Guidance on PBPK for your drug development program

Feb 24, 2021

Report

New Medicines, Novel Insights: Advancing rare disease drug development

May 22, 2023

Blog

U.S. drug price reform of 2022: What does the Inflation Reduction Act mean for drug manufacturers?

Aug 17, 2022

Article

New endpoints for early-stage cancer are gaining regulatory traction

Jan 28, 2022

Article

How biotechs can strengthen their value story with advanced analytics

Feb 15, 2022

Video

On-demand webinar: An expert guide to EU-CTR

Mar 10, 2022

Article

New FDA Guidance Addresses the Need for Data-Generation Strategies Across the Drug Development Lifecycle

May 10, 2022

Related Insights

Blog

AI Milestones: FDA’s ISTAND program accepts AI-based assessment tool for depression

Mar 19, 2024

Playbook

Are you using real-world evidence?

Feb 1, 2023

Blog

Regulatory acceptability of AI: Current perspectives

Mar 7, 2024

Blog

Summary and assessment: Using Artificial Intelligence & Machine Learning in the Development of Drug & Biological Products: Discussion Paper and Request for Feedback (FDA)

Mar 7, 2024

Blog

Summary and assessment of EMA’s reflection paper on the use of artificial intelligence (AI) in the medicinal product lifecycle

Mar 7, 2024

Blog

Leveraging the draft FDA Guidance on PBPK for your drug development program

Feb 24, 2021

Show more